期刊文献+

系统性硬化症消化道受累诊疗进展 被引量:3

Progress of gastrointestinal involvement in systemic sclerosis
原文传递
导出
摘要 系统性硬化症是一种以皮肤增厚为特征的自身免疫性疾病,消化系统为仅次于皮肤的第二大受累器官,其临床表现不特异,早期易被忽视,从而影响患者预后及生存质量.本文将对近几年系统性硬化合并消化系统并发症在病理、临床特征、患者管理及治疗方面的现状及进展进行综述,旨在提高内科医生尤其风湿病及消化等专业医生对该病的重视程度,以达到早期诊治及早改善预后的目的. Systemic sclerosis is an autoimmune disease characterized by skin thickening and tightness.Digestive system is the most commonly damaged system secondary to skin,and as to unspecific clinical manifestations,this complication is often ignored in the early,the prognosis and quality of life of patients will be affected.This article overviews the recent research developments on pathology,clinical features,management of systemic sclerosis with digestive system involvement,to draw attention to early diagnosis and treatment of this condition for the improvement of the prognosis.
出处 《中华全科医师杂志》 2017年第9期725-728,共4页 Chinese Journal of General Practitioners
关键词 硬皮病 系统性 消化系统 疾病特征 诊断 治疗 Scleroderma,systemic Digestive system Disease attributes Diagnosis Therapeutics
  • 相关文献

参考文献2

二级参考文献45

  • 1Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol,2003 ,21:241-248.
  • 2Weaver AL. Differentiating the new rheumatoid arthritis biological therapies. J Clin Rheumatol,2003 ,9 :99-114.
  • 3Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-intedeukin-6 receptor antibody: a muhieenter, double-blind, placebo-controlled trial.Athritis Rheum ,2004,50 : 1761-1769.
  • 4Grillo-Lopez A. Rituximab: an insider's historical perspective.Semin Oncol, 2000,27 ( 6 Suppl 12 ) :9-16.
  • 5Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum, 2000, 43:1346-1352.
  • 6Allali F, Roux C, Koha S, et al. Infliximab in the treatment of spondyloarthropathy, bone mineral density effect. Arthritis Rheum,2001,44 : S89.
  • 7Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled muhicentre trial.Lancet,2002,359 : 1187-1193.
  • 8Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha ( infliximab ) versus placebo in active spondylarthropathy. Arthritis Rheum,2002,46:755-765.
  • 9Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis,before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum,2003,48 : 1126-1136.
  • 10Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol,2002,29:118-122.

共引文献9

同被引文献26

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部